The US Food and Drug Administration has approved the first haematopoietic progenitor cell-cord cell therapy. Called Hemacord, the product is manufactured by the New York Blood Center Inc of New York. ---Subscribe to MedNous to access this article--- Regulation & Policy Regenerative Medicine
